Could hepatitis B vaccine act as an adjuvant to lower risk and relapses of cancer?


Altinoz M. A. , ÖZPINAR A. , Ozpinar A., Hacker E., Elmaci I.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol.46, no.8, pp.694-704, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 46 Issue: 8
  • Publication Date: 2019
  • Doi Number: 10.1111/1440-1681.13096
  • Title of Journal : CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
  • Page Numbers: pp.694-704

Abstract

In this review article, we hypothesize that Hepatitis B Virus Vaccine (HBV-V) and certain antigens of Hepatitis B Virus (HBV) could act as anticancer immunoadjuvants in addition to their role of preventing HBV-associated liver cancer. Evidence suggests that in animal breast cancer and melanoma models, combining hepatitis B-surface antigen (HBsAg) with other cancer antigens resulted in enhanced antitumour activity. HBsAg shares antigenic mimicry with healthy and malignant cells including squamous epithelia, thymic epithelia, bladder- and colon cancer cells. There exist anecdotal reports and small case series about spontaneous remission of leukaemias and neuroblastoma following acute HBV-infection. Recent studies also exist showing HBV-carrier state is a good prognostic factor for intrahepatic cholangiocarcinoma. Further epidemiological studies and animal experiments are necessary whether HBV-Vs exert additional immunoadjuvant benefits besides lowering the risk of liver cancer.